Sangamo Therapeutics Announces Board Changes and Shareholder Votes
Ticker: SGMO · Form: 8-K · Filed: Jun 16, 2025 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | 8-K |
| Filed Date | Jun 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, officer-compensation, shareholder-vote, filing
Related Tickers: SGMO
TL;DR
Sangamo's board is shaking up with new directors and comp changes; shareholder vote coming.
AI Summary
Sangamo Therapeutics, Inc. announced on June 12, 2025, a series of significant corporate actions. These include the departure of two directors, the election of two new directors, and changes in officer compensation arrangements. Additionally, the company is submitting matters to a vote of its security holders and filing financial statements and exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and officer changes, along with shareholder votes, introduce a degree of uncertainty regarding future strategic direction and operational stability.
Key Numbers
- 000-30171 — SEC File Number (Sangamo Therapeutics' SEC filing identifier.)
Key Players & Entities
- Sangamo Therapeutics, Inc. (company) — Registrant
- June 12, 2025 (date) — Date of earliest event reported
- 501 Canal Blvd., Richmond, California 94804 (address) — Principal executive offices
- 68-0359556 (tax_id) — IRS Employer Identification No.
FAQ
Who are the departing directors and the newly elected directors?
The filing indicates the departure of directors and the election of new directors, but their specific names are not detailed in this summary section of the 8-K.
What specific matters will be submitted to a vote of security holders?
The filing states that matters will be submitted to a vote of security holders, but the exact proposals are not enumerated in this section.
What are the key changes in the compensatory arrangements of certain officers?
The filing mentions changes in compensatory arrangements for certain officers, but the specifics of these changes are not provided in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 12, 2025.
What is Sangamo Therapeutics' principal executive office address?
Sangamo Therapeutics' principal executive office is located at 501 Canal Blvd., Richmond, California 94804.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding SANGAMO THERAPEUTICS, INC (SGMO).